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Abstract 
Adolescent pregnancy is a significant cause of global morbidity and mortality.  
Adolescents who become pregnancy have lower educational attainment, are more likely 
to live in poverty, and have lower wellbeing.  Increasing access to hormonal 
contraceptives and long acting reversible contraception is highly effective in reducing 
adolescent pregnancies. This narrative review covers key aspects of the provision of 
contraception to adolescents, including confidentiality, counseling, and data supporting 
expanded access to adolescents.  We provide information for pediatric providers to start 
adolescent patients on contraceptives, including a detailed description of each method, 
including effectiveness, use, starting, side effects and benefits.  Tools for counseling and 
prescribing are provided. 
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Introduction 
The Problem of Adolescent Pregnancy 
Although adolescents have many options for effective contraception, adolescent 
pregnancy continues to be a significant cause of morbidity and mortality worldwise.   
Approximately sixteen million teens worldwide became pregnant in 2014.1  Many 
disparities exist; 95% of pregnancies among adolescents occur in low and middle income 
countries. In low income countries, pregnancy can be the result of early marriage, sexual 
coercion, or abuse.2 In the United States, which has one of the highest teen pregnancy 
rates in developed countries,3 large ethnic and geographical differences exist. American 
teens who are Hispanic or black have higher pregnancy rates than non-Hispanic whites, 
and pregnancy rates are much higher in some states (southern and southwestern states) 
than in other areas of the country. These differences likely represent larger 
socioeconomic disadvantages.4  Pregnancy during adolescence can have lifelong health 
and socioeconomic effects: in the U.S., only 2% of adolescent mothers go on to graduate 
from college and are less likely to graduate high school than their peers.5 Worldwide, 
lower scholastic achievement is also seen, along with pregnancy complications 
representing the leading cause of death in 15-19 year olds in low and middle income 
countries.1 
 
Effectiveness of Contraception 
Effective contraception lowers adolescent pregnancy rates, with the greatest declines 
occurring when adolescents have easy access to long acting reversible contraceptives.6,7 
This relationship between access to effective contraceptives and adolescent pregnancies 
can been seen on a population level.  For example, the United States has seen a drop in 
adolescent pregnancy, birth, and abortion rates, although rates of sexual activity have not 
changed among American teens,8 with much of the decline among adolescents can be 
attributed to improved contraception use.9 In addition to preventing unplanned 
pregnancy, contraceptives can have medical benefits for teens, such as dysmenorrhea 
management, limiting menstrual blood loss, and acne treatment.  Contraceptives today 
are safe, and clear guidance for prescribing and use in patients with medical conditions 
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are readily available to providers.10 This narrative review highlights best practices and 
new developments in the provision of highly effective LARCs and hormonal 
contraceptives to adolescents.   Information on barrier methods and less effective 
methods such as periodic abstinence can be found elsewhere.11 
 
Counseling and Starting Contraception  
 
Confidentiality 
In the setting of contraceptive provision, confidentiality involves allowing the adolescent 
to control who has access to their sexual health information.  For adolescents, 
confidentiality is a cornerstone to effective contraceptive counseling.13,14 Questions 
regarding sexual behavior, sexually transmitted infections, and contraception should 
always be asked confidentially; Policies limiting confidentiality have been associated 
with less willingness of teens to disclose and less access to family planning services, 
leading to higher pregnancy rates.15.16,17,18. As a result, maintaining confidentiality is a 
critical piece when working with adolescents.17,18,19,20  
 
Human Rights and Adolescent Sexual Health 
The Convention on the Rights of the Child identifies access to sexual and reproductive 
health information and services as a basic human right for adolescents.  The Convention 
states that adolescents themselves are considered active rights holders, and should be 
allowed to progressively exercise these rights with their evolving capacity. As part of an 
adolescent’s right to the highest attainable health is the right to sexual and reproductive 
health information and services, including contraception and safe abortion.21 
 
Role of Parents 
While adolescents have rights to confidentiality, it can often be helpful to involve a 
parent or another trusted adult in sexual health decisions. Parents play an important and 
often under-appreciated role in communicating with their child about sex and facilitating 
access to sexual health services.22  Parental communication and support is associated with 
a delayed onset of sex, and safer sex behaviors.23,24 As long as the adolescent feels 
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comfortable and safe, we encourage adolescents to talk to a parent or other trusted adult 
about sex and sexual health decisions. Human rights documents recommend a shift in 
parents’ roles for adolescents from that of decision-maker and caregiver to the provision 
of direction, guidance, and a safe environment, while taking into account the adolescents’ 
views.24 
 
Start asking about sexual behavior early 
Most adolescents initiate sexual activity between the ages of 15-19.2,28 Because of the 
enormous developmental chances across adolescence, interviews about sexual behavior 
and pregnancy prevention must be sensitive to developmental age and ensure 
confidentiality about the conversation.  There is no specific age to start this conversation. 
Instead it should represent a continuum of conversations about sexuality and sexual 
development. For example, school aged children should be taught personal safety and 
appropriate names for body parts and as they age, this conversation shifts to also include 
sexual behavior.  
 
Counseling approaches 
Motivational interviewing (MI) allows counseling to be done in a non-judgemental, 
caring and patient-centered manner .29 Open ended questions and other motivational 
interviewing (MI) approaches allow providers to  explore knowledge of pregnancy risks, 
sexually transmitted infection prevention, and generally attitudes towards sex.  
Interventions using MI have been shown to improve sexual health outcomes.30 MI allows 
providers to engage adolescents in the conversation and give them control of the medical 
decision making about their reproductive health needs (Box 1.). Teens who are not yet 
sexually active should be encouraged to delay sex, be assessed for future sexual 
behaviors, and be provided with information and contraception (if indicated) to meet 
anticipated sexual health needs. Services available at your office, the patient’s working 
knowledge of contraception, and reproductive health resources should be discussed to 
foster health promoting behaviors should their decisions around sex change. Guidelines 
for general reproductive health interviews allow providers to obtain the necessary 
information to guide counseling and provision of services for pregnancy and sexually 
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transmitted infection (STI) prevention.  One example is the U.S. Centers for Disease 
Control and Prevention (CDC) interview structured around “5 Ps”: partners, prevention 
of pregnancy, protection from STIs, sexual practice, and past history of pregnancy and 
STI; example questions are available on their website.31 
 
Adolescents have wide developmental variation in sexual health, knowledge, behaviors, 
attitudes and access to services.   Providers will need to assess what adolescents know 
about various forms of contraception, and the sources of that information (sexuality 
education programs, family, friends, internet searches).  Research suggests that families, 
friends and partners are strong influences on the uptake and choice of contraceptive 
methods, as a result an assessment of family and friends’ experiences is  often is a good 
place to start.32,33 Myths about contraceptives, such as the shot makes you infertile, 
should be addressed and acknowledged. Side effects should be discussed however, 
reassured at the same time that you, the provider, are there should they occur. Benefits 
should also be highlighted.  
 
Websites designed for teens on contraception can be helpful aids in going through 
methods and also provide orientation to resources available for home research, or to help 
your patient discuss with their parents (if desired). Additionally, resources on 
contraception should be part of the display of information available in waiting rooms. 
Side effects should be discussed however, reassured at the same time that you the 
provider are there should they occur.  All contraceptives will have some impact on 
menstruation and views on this impact explored. Additionally, knowledge of how teens 
experience their periods should be considered in counseling. For example, teens with 
dysmenorrhea or menorrhagia can see benefits on pain and flow with some 
contraceptives, but these symptoms may worsen on others.  
 
Guidelines for Pediatricians 
Current guidelines and best practices for the provision of contraception include the 
Medical Eligibility Criteria (MEC) and Selected Practice Recommendations (SPR) 
available from the World Health Organization (WHO) and U.S. CDC(see Box 2).10,11,12 
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While these resources are for all women, adolescent-focused recommendations are 
included when they differ from adult recommendations. The SPR emphasizes a woman’s 
choice and self-determination, and gives guidance on use and side effect management of 
all contraceptive options.   While contraceptives are very safe for most patients, they are 
medications and devices, and individuals some medical conditions may be at higher risks 
for side effects and complications. The U.S. Medical Eligibility Criteria and the WHO 
Medical Eligibility Criteria are both available resources for providers to assist and 
assessing potential risks.10,11 These guidelines categorize risk by degree of risk and 
potential benefit.   This review will identify MEC Category 4 medical conditions (do not 
use under any circumstances) as contraindications, and MEC Category 3 medical 
conditions (risks generally outweigh benefits, but can be individualized to patient and 
used with caution) as use with caution. 
 
Best practice guidelines recommend starting counseling with the most effective method 
first, followed by the second most effective method, and end with the least effective 
method. These recommendations are based upon large community interventions which 
demonstrated that counseling from most to least effective and removing financial and 
transportation barriers to LARCs increase uptake of more effective methods and reduce 
subsequent pregnancies.6,7 Long acting reversible contraceptives (LARCs) have emerged 
in recent years as first line options for teens due to their high efficacy and safety. In many 
ways, LARCs are ideal for teens as they offer a high level of privacy (once they are 
placed, there is no need for frequent clinic visits or trips to the pharmacy), little to no 
challenges to adherence, and rapid return to fertility once removed. Fewer 
contraindications to use exist with these methods.  The American Academy of Pediatrics 
(AAP), Society for Adolescent Health and Medicine (SAHM) and the American College 
of Obstetrics and Gynecology (ACOG) recommend these contraceptives as first line 
options for teens.12,34,35 
 
The SPR recommends reducing barriers to contraception, such as cost, transportation, and 
the need for pelvic exams. This recommendation is especially relevant to teens. Risk of 
current pregnancy should be assessed per SPR guidance,11 and if low risk or switching 
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from another form of contraception that was used reliably, contraception should be 
started at that visit. Urine pregnancy tests, STI testing, and physical examinations are 
usually not required to start contraception. If risk of pregnancy is unknown, all 
contraceptives other than intrauterine devices and systems can be started and pose limited 
risks to early pregnancy.36,37If contraception is started and pregnancy risk cannot be 
assessed at time of initiation, emergency contraception offered, and a urine pregnancy 
test should be performed 2-4 weeks after starting.  
 
A common instance when it is hard to assess risk of pregnancy is when your patient has 
not been on reliable contraption and engaged in sex 1-2 weeks prior to the appointment 
(depending on the type of pregnancy test used). Emergency contraception should be 
strongly considered in this case. Levonorgestrel, ullipristal acetate and the copper IUD 
are all medications used for emergency contraception. Detailed guidance on prescription 
and use is readily accessible on multiple websites online, including that of the World 
Health Organization (See Box 2).38 Data support the advanced provision of 
levonorgestrel and ullipristal acetate for adolescents using no contraception or a less 
effective forms of contraception.39,40 
 
Adolescents and young adults have the highest rates of STIs.  Thus condoms should be 
encouraged to be used in combination with all other methods. Alone, condoms as 
typically used are moderately effective for contraception, but are the only method that 
prevents sexually transmitted infection. An additional point to emphasize is the fact that 
together with a more effective hormonal or LARC method, they can boost contraception 
effectiveness to near 100%.  
 
Contraception Methods 
All contraceptive methods available to adults are available to teens, with the exception of 
sterilization. Contraceptives vary by the presence and type of hormones and duration of 
action. LARCs are first line options for teens and encompass the implant and intrauterine 
devices. This review is organized in the same manner as counseling, in order of most to 
least effective. An overview of each method is provided below, with links to prescribing 
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instructions and online resources (see Box 2). While contraception is very safe overall, 
some carry unacceptable risks in those with certain medical conditions; specific evidence 
based medical eligibility for criteria for contraception is easily accessible through the 




Hormonal implants are highly effective forms of contraception containing a progestin. In 
comparison to earlier implants with five rods, the implants available today are single rod 
devices containing etonorgestrel or double rod devices containing levonorgestrel. They 
are placed subdermally in the upper arm. The etonorgestrel rod is effective up to 3 years 
while the levonorestrel double rod is effective up to 5 years. Both devices have typical 
use effectiveness rates over 99%. Implants prevent pregnancy by suppressing ovulation 
and thickening cervical mucous.  
 
Implants can be easily placed. Once placed, there are few barriers that exist affecting 
compliance (ex. Clinic visits, patient responsibility at home). Placement is a well-
tolerated, fast, and simple procedure that is not overly intimidating: with or without local 
anesthesia, a specially designed inserter slides the implant under the skin. The patient’s 
only responsibility for effective use is getting it replaced on time, when the 3 or 5 years 
have expired. They offer a high degree of privacy - although they can be easily palpated 
in the upper arm when skin is held taught, they are relatively invisible under the skin with 
little to no scarring at their insertion site.  Training is easily obtained and implants can be 
placed by pediatricians and other primary care providers during a regular office visit. 
 
Implants have relatively few serious side effects and risks. Although implants suppress 
ovulation, follicular suppression does not occur and normal estrogen levels are 
maintained. Absolute contraindications are few and exist in conditions uncommonly seen 
in teens: Breast cancers. Caution should be used when prescribing to patients with 
systemic lupus erythematous, advanced liver disease, or unexplained vaginal bleeding. 
Disruption of regular menses is the most common side effect and can lead to frequent and 
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irregular bleeding. Such bleeding is generally not harmful and does not lead to anemia 
however, can affect quality of life and desire for continuation of the method. Advance 
counseling of this side effect, having yourself available to the patient when it happens for 
reassurance, and trial of NSAIDs or estrogens can help support patients who have 
undesired bleeding. This side effect renders the implant less reliable for complete 
menstrual suppression however, its few contraindications and side effects make it a 
desirable form of contraception for medically complex patients as well as teens desiring 
very highly effective contraception.  
 
Intrauterine Devices (IUDs) 
Another good option for teens desiring highly effective contraception is intrauterine 
contraception. Many design changes have occurred over the years in this group of 
contraceptives. Today’s T-shaped IUDs and IUSs are very safe, easy to insert, and more 
effective than prior versions.  
 
Myths around infection and IUDs still exist today and should be explained and counseled 
on.  IUDs increase the risk of pelvic infection only in the first month after insertion; 
afterwards, an individual’s risk of pelvic infection returns to baseline.  While adolescents 
and young adults have the highest age-specific rates of sexually transmitted infections, 
outside of the first month, IUDs do not increase that risk.41It is recommended that IUDs 
and IUSs are not placed when there is an acute pelvic infection. However, there is no 
need to have a documented negative test prior to insertion.11 If evidence for infection 
exists during the pelvic exam performed immediately prior to placement (such as 
purulent cervical discharge or uterine tenderness), the procedure should be delayed until 
testing and treatment has been completed. If the exam is normal, testing for Chlamyidia 
trachomonitas or Neiserria gonorrheae can be done during placement and these 
asymptomatic infections treated routinely. If the adolescent with an IUD develops pelvic 
inflammatory disease, standard treatment should be implemented and the IUD removed 
only if the adolescent fails standard of care treatment.42 The other contraindications 
relevant to teen are uterine anomalies (e.g. accessory uterine horns) that may affect their 
ability to host a device. Some worry about younger adolescents having an adequate 
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uterine size and favor smaller devices; However progestin containing IUDs have been 
used extensively in adolescents with disabilities, including very young and physically 
small adolescents.43,44  This clinical experience demonstrates that the adolescent with 
normal anatomy can tolerate all of the devices on the market, bimanual examination at 
the time of placement is recommended to assess uterine size and the presence of 
anomalies.  
 
Two forms of IUDs are on the market in the US and Europe: the copper IUD and 
progestin containing IUD. Once place, progestin IUDs are effective between 3-5 years 
(depending on the specific device) and the copper IUD is effective up to 12 years.  All 
have a greater than 99% effectiveness and are similar in design and placement procedure.  
 
 Progestin IUDs: : The progestin IUDs are levonorgestrel releasing devices that 
work primarily locally: The progestin thickens cervical mucous and induce endometrial 
 atrophy. They may suppress ovulation (although, most continue to ovulate).44 
Progestin IUDs vary by the amount of hormone, length of time they are effective, and 
size. Differences in the amount of hormone create differences in menstrual suppression 
rates.  Most individuals on any of the progestin IUDs experience lighter periods, and the 
higher the amount of levonorgestrel, the more likely amenorrhea will result. Progestin 
IUDs are great options for teens with a history of dysmenorrhea, menorrhagia, or desiring 
menstrual suppression.32 They have been used extensively to induce amenorrhea for 
adolescents with mobility-related and cognitive disabilities because of difficulties related 
to hygiene.43 
 
The non-hormonal copper-containing IUD induces a sterile inflammatory response in the 
uterus, rendering it inhospitable to sperm. Additionally, the copper IUD is the most 
effective form of emergency contraception and can be used up to 10 days after 
unprotected sex, but most often recommended within 5 days.46 The main side effect is 
effects on the menstrual cycle. Unlike progestin IUDs, regular ovulation and menses 
continue when on the copper IUD. However, bleeding can be heavier and accompanied 
by more cramping than an individual’s natural periods. Because the copper IUD has no 
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hormones, it is the safest option for teens with significant histories of thromboembolic 
disease or serious complex health conditions that make pregnancy dangerous.11 
 
IUDs are inserted in the office during a pelvic exam. The pelvic exam is necessary in 
order to assess uterine size and, can be done as part of placement. Many teens have never 
had a pelvic exam and find the prospect intimidating. Taking time to describe the 
procedure and answer questions, emphasizing it is more awkward than painful, and 
reminding your patient to keep in mind the high effectiveness of these devices and 
minimal effort required once placed are all important points to emphasize. If family or 
friends are successfully using an IUD, you can suggest the adolescent ask that person 
about what placement is like.  The website Bedsider.org features videos of young women 
talking about their experiences with the devices.  Cervical blocks and non-steroidal anti-
inflammatory drugs (NSAIDs) have little evidence to support their use in improving the 
placement experience in adults;47 however, NSAIDs can be offered prior to the procedure 
to help with post procedure cramping. 
 
Expulsion and irregular bleeding are the two main side effects of these methods. 
Expulsion is when the uterus contracts to push the device out of the uterus – either 
completely (into the vagina) or partially (into the cervical canal). Expulsion rates vary 
among studies but, overall are very low. Patients should be instructed to call if they 
experience unexplained cramping or bleeding.  If an expulsion is suspected, providers can 
image with a pelvic ultrasound. 
 
Progestin Injectable Contraception 
The three progestin-only injectable contraceptives are depo medroxyprogesterone acetate 
(DMPA) intramuscular injection, the DMPA subcutaneous injection, and norethisterone 
enanthate (NET-EN).  Only the two DMPA formulations are available in the United 
States; NET-EN is available in other countries.  The subcutaneous DMPA injection 
contains slightly less hormone and can be administered at home. Effectiveness is not as 
high as LARCs but, fairly good at 94% with typical use (it is more than 99% with perfect 
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use).45 The injectable contraceptives work by suppressing ovulation and follicular 
development. The resultant lower estrogen state leads to thinning of the endometrium and 
inhibits endometrial proliferation.  
 
Effectiveness can be affected by a teen’s ability to see a provider at the required injection 
interval (3 months for DMPA and 2 months for NET-EN). This is a significant point to 
consider as teens have many barriers to health care such as transportation, lack of teen 
friendly clinic policies, confidentiality concerns, and continuous health care (a stable 
clinic or stable insurance). Frequent visits can be difficult for busy teens in school, 
working, participating in sports, or involved in extracurricular activities. Frequent visits 
can often diminish the ability to have privacy from family with regards to contraception; 
however, because it is an injection, if an individual can come to their appointment 
independently, there is no evidence of being on contraception otherwise.  
 
Individuals on progestin injectables have high rates of amenorrhea and, of all of the 
contraceptives, it is among the most reliable contraceptives for menstrual suppression. 
Amenorrhea usually does not happen immediately; instead, women have fewer days of 
bleeding or spotting with time. Because of its strong ovarian suppression, DMPA can be 
helpful in teens who have menstrual related symptoms (such as severe dysmenorrhea or 
endometriois, vomiting, some forms of headaches, catamenial seizures, or behavioral 
concerns). It can be used while breastfeeding. Like the implant and IUDs, it does not 
contain estrogen, and has fewer contraindications than combined hormonal 
contraceptives.  
 
Progestin injectables have few absolute contraindications relevant to teens. However, it 
has several side effects of concern to teens. Of all contraceptives, DMPA is the only one 
with evidence of weight gain.48 Assessing current diet and providing dietary counseling is 
very important when starting DMPA in overweight teens. A second concerning side 
effect is decreased bone mineral density (BMD).49,50 This is due to the relative 
hypoestrogenic state DMPA creates. The decrease in BMD appears reversible once the 
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medication is stopped,51,52 but long term effects in late adulthood are unknown at this 
time. Teens with risk factors for lower BMD, such as low body mass indexes, chronic 
corticosteroid use, and immobility, should be counseled on this and protective bone 
health activities encouraged such as weight bearing exercise and consuming adequate 
dietary calcium.52 Exercise should be encouraged for both weight gain and decreased 
bone mineral density (BMD). Other side effects of DMPA are rarer but, represent 
conditions with high prevalence in teens. Depression, headaches, and acne can be 
worsened. DMPA can also lower sex drive.  
 
Despite its side effect profile, progestin injections are a well-known and highly effective 
forms of contraception that requires little compliance other than keeping appointments. 
Counseling should address negative side effects, but also highlight it’s high effectiveness, 
ease of administration, and desirable side effects (amenorrhea).  
 
Combined Hormonal Contraceptives (CHCs) 
CHCs contain both estrogen and progestins and come in 4 different modes of 
administration: oral, transdermal, transvaginal, and the combined contraceptive injection.  
The combined contraceptive injection is not available in the US.   COCs, the transdermal 
patch, and the vaginal ring have a similar effectiveness of approximately 91% with 
typical use.53 Side effects and risks are also similar. The primary mode of action for 
CHCs is suppression of ovulation, through lowering pituitary hormone release.  While 
progestin only contraceptives are safe to use while breast feeding, CHCs are not. 
 
Used traditionally, these medications have 4 week cycles of three weeks of ovarian 
suppression via hormonal pills followed by one week of hormone withdrawal and 
subsequent menses via placebo pills. All can also be used continuously by not taking the 
placebo week. Unlike the progestin only contraceptives, when used traditionally, a 
regular pattern of menses is maintained. CHCs can be easily switched from one to 
another or used continuously.  With combined oral contraceptive pills (COC), the 
prescriber can change the dose of estrogen and formulation of progestin estrogen 
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increased or decreased or progestin changed to “personalize” this medication to an 
individual’s side effects or desired level of menstrual suppression.   
 
CHCs have been used more than any other contraceptive to manage medical conditions.54 
They lessen menstrual blood loss through lighter, shorter periods. They also can 
significantly decrease or stop cramps. If periods remain heavy or painful with monthly 
cycles, extending cycles to every 3 months or more lets individuals experience these 
symptoms less often or schedule periods for a time when periods won’t disrupt important 
life events.  In cases of menorrhagia, multiple pills or patches can be used for brief 
periods of time to give a larger dose of estrogen and slow or stop menses. For individuals 
with endometriosis, menstrual cycle syndromes or symptom flares can be treated with 
continuously administered CHCs.54 
 
CHCs also decrease circulating free testosterone by increasing levels of sex hormone 
binding globulin. This effect is why CHCs are used to treat acne and mild cases of 
hirsuitism. Lowering circulating testosterone with CHCs is also used in individuals with 
polycystic ovarian syndrome, improving androgenic signs and regulating periods. 
 
Although CHCs have relatively more contraindications than progestin only 
contraceptives, they are still a safe choice for most adolescents.  For adolescents with 
chronic medical conditions, providers will need to consult the MEC and, in some cases, 
the relevant pediatric subspecialist. CHCs are contraindicated in adolescents with a 
personal history of thromboembolic disease or a thrombogenic mutation because of an 
increased risk of thromboembolism. CHCs are also contraindicated for adolescents with 
migraine headaches who experience a true aura due to an increased risk of stroke. CHCs 
should be used with caution in controlled hypertension and are contraindicated in 
uncontrolled hypertension.11 
   
Many adolescents with medical problems have congenital conditions, and because the 
contraindication data come from studies of adult conditions, the MEC can be difficult to 
apply.  For example, CHCs may or may not be appropriate for adolescents with a history 
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of congenital heart disease. Estrogen is contraindicated in severe valvular disease.  For 
some adolescents with milder forms of congenital heart disease with definitive repairs, 
such as those with simple atrial or ventricular septal defects, CHCs may be safe.  
However, for those whose anomalies and repairs have resulted in valvular dysfunction, 
CHCs should not be used.  A full list of contraindications and cautions can be found in 
the WHO MEC.10 
 
CHC counseling should screen for the contraindications, review risks, side effects, and 
benefits, and assist the adolescent in making a personal decision.   Some will want to 
avoid side effects; for others, particularly those with menstrual symptoms, CHCs can 
dramatically improve well-being.  Signs of thromboembolic disease should be fully 
explained as well as side effects such as breast tenderness and nausea. Compliance 
factors, such as ability to take the medication regularly (daily, weekly or monthly per 
method) and filling the prescription at the pharmacy, should be discussed. Utilizing cell 
phone alarms, working administration into a daily routine, and parental involvement are 
all tools to improve compliance. 
 
Contraception Provision in Practice 
Because there are many LARC and hormonal methods available, and interviewing 
requires time to build rapport and establish confidentiality, the provision of effective 
contraception to adolescents can appear a daunting task.  However, pediatric providers 
occupy a place of trust with families and adolescents, and are often the only point for 
adolescent to access family planning.  Additionally, many adolescents are familiar with 
contraception through use by family members or friends, educational programs, and 
online resources.  By assessing adolescents’ baseline knowledge and experiences (an 
important part of MI), and keeping the following key points in mind, pediatricians can 
incorporated LARCs and hormonal contraceptives into their pediatric practice.  
 
 Make clinic space teen friendly: Have separate waiting areas for teens with 
relevant health information available including information on contraception and 
confidentiality. 
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 Begin sexuality discussions during early adolescence.  This screens for early risk 
behavior, signals to adolescents that you are willing to talk about difficult topics, 
and trains parents both to communicate with their teens about contraception and 
to allow adolescents the privacy and responsibility of talking to a provider on 
their own. 
 While contraceptives are very safe for most patients, international and US-based 
resources allow providers to quickly identify contraindications and risks for 
medically complex adolescents. 
 Counsel in order of most to least effective methods, discussing side effects in light 
of both contraceptive and medical benefits.  
 Be available after prescription to address side effects, compliance, and 
satisfaction. 
 Adolescents whose providers are willing to address difficult topics such as 
pregnancy prevention and contraception are more engaged in their own health 
care (Brown and Wissow).  Counseling and providing effective contraception not 
only prevents unintended pregnancy, but can enhance your adolescent patient’s 
journey through a successful adolescence 
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Box	4:	Example	English‐language	Online	Resources	for	Adolescents	(not	a	complete	
list)	
	
Resource	 Description	
Bedsider.org	 A	birth	control	information	network	for	adolescents	and	
young	adults,	sponsored	by	the	USA	National	Campaign	to	
Prevent	Teen	and	Unplanned	Pregnancy.	
	
Stayteen.org	 A	sexual	health	site	for	adolescents	that	includes	
contraceptives	as	well	as	information	on	topics	such	as	
health	relationships	and	dating	violence;	sponsored	by	the	
USA	National	Campaign	to	Prevent	Teen	and	Unplanned	
Pregnancy.	
	
SexEtc.org	 A	sexuality	web	site	written	by	and	for	adolescents;	
includes	contraceptives	as	well	as	nuanced	information	on	
gender	and	sexuality;	sponsored	by	the	USA	organization,	
Answer,	based	at	Rutgers	University.	
	
DaSubjectMatter.org	 A	sexual	health	information	website	and	mobile	platform	
for	Nigerian	adolescents	and	young	adults,	sponsored	by	
Planned	Parenthood	Global,	the	Nigerian	government,	and	
the	United	Nations	Population	Fund.		
	
Brook.org.uk	 A	sexual	health	website	for	young	people	under	25	years	in	
the	United	Kingdom,	with	information	and	links	to	service	
sites,	sponsored	by	Brook.		Includes	a	24/7	Ask	tool.	
	
 
